论文部分内容阅读
目的探讨瑞舒伐他汀对高脂血症患者血清超敏C反应蛋白(Hs-CRP)的影响。方法将73例患者随机分为3组,治疗组1使用瑞舒伐他汀5 mg/d,治疗组2使用瑞舒伐他汀10 mg/d,对照组使用阿托伐他汀10 mg/d,治疗8周,分析3组患者治疗前后血清Hs-CRP水平和血脂水平。结果治疗组1、治疗组2和对照组患者治疗后总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)分别为(4.36±0.73)mmol/L、(1.36±0.61)mmol/L、(2.84±0.78)mmol/L和(4.09±0.65)mmol/L、(1.31±0.61)mmol/L、(2.54±0.62)mmol/L及(4.49±0.39)mmol/L、(1.41±0.56)mmol/L、(2.76±0.39)mmol/L与治疗前比较均下降(P<0.05)。3组患者治疗后血清Hs-CRP水平分别为(1.54±1.29)mg/L、(1.36±1.05)mg/L和(1.56±1.81)mg/L,均低于治疗前(P<0.05),3组间差别无统计学意义。结论瑞舒伐他汀能安全有效的治疗高脂血症,并且能显著降低血清Hs-CRP水平,有益于减少心血管事件的发生。
Objective To investigate the effect of rosuvastatin on serum high sensitive C-reactive protein (Hs-CRP) in patients with hyperlipidemia. Methods 73 patients were randomly divided into three groups, the treatment group 1 with rosuvastatin 5 mg / d, the treatment group 2 with rosuvastatin 10 mg / d, the control group with atorvastatin 10 mg / d, treatment Eight weeks later, the levels of serum Hs-CRP and blood lipid in three groups before and after treatment were analyzed. Results After treatment, the total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) in treatment group 1, treatment group 2 and control group were (4.36 ± 0.73) mmol / L and ± 0.61 mmol / L, 2.84 ± 0.78 mmol / L, and 4.09 ± 0.65 mmol / L, 1.31 ± 0.61 mmol / L, 2.54 ± 0.62 mmol / L and 4.49 ± 0.39 mmol / L, (1.41 ± 0.56) mmol / L and (2.76 ± 0.39) mmol / L, respectively, decreased compared with those before treatment (P <0.05). The levels of Hs-CRP in the three groups after treatment were (1.54 ± 1.29) mg / L, (1.36 ± 1.05) mg / L and (1.56 ± 1.81) mg / L, The difference between the three groups was not statistically significant. Conclusion Rosuvastatin can be used safely and effectively in the treatment of hyperlipidemia, and can significantly reduce the level of serum Hs-CRP, which is beneficial to reduce the incidence of cardiovascular events.